CERo Therapeutics Holdings, Inc.
CERO
$0.01
$0.00-9.91%
OTC PK
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -78.92% | |||
| Gross Profit | -- | 78.92% | |||
| SG&A Expenses | -33.97% | 92.14% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.93% | -6.81% | |||
| Operating Income | -6.93% | 6.81% | |||
| Income Before Tax | -29.63% | 6.50% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -29.63% | 6.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -29.63% | 6.50% | |||
| EBIT | -6.93% | 6.81% | |||
| EBITDA | -7.16% | 6.86% | |||
| EPS Basic | 93.67% | 64.45% | |||
| Normalized Basic EPS | 32.21% | 92.11% | |||
| EPS Diluted | 93.67% | 64.45% | |||
| Normalized Diluted EPS | 32.21% | 92.11% | |||
| Average Basic Shares Outstanding | 91.92% | 1,084.52% | |||
| Average Diluted Shares Outstanding | 91.92% | 1,084.52% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||